Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.
about
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpointsMurine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).Personalized therapy for metastatic melanoma: could timing be everything?IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanismsSynergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.Optimal population of FoxP3+ T cells in tumors requires an antigen priming-dependent trafficking receptor switchIL-35-mediated induction of a potent regulatory T cell population.Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.Theratope vaccine (STn-KLH).Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.The effects of cyclophosphamide and irradiation singly and in combination upon SaI growth in A/J mice.Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma.Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessmentVaccination with Theratope (STn-KLH) as treatment for breast cancer.In vivo detection and partial characterization of effector and suppressor cell populations in spleens of mice with large metastatic fibrosarcomas.Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal studyGeneration and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunityEffect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejectionTherapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action.Dendritic cells that have interacted with antigen are targets for natural killer cells.Multiple cancers. Tumor burden permits the outgrowth of other cancersSpecific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cellsT cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity.Cutaneous leishmaniasis. The defect in T cell influx in BALB/c mice.Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.The dual nature of specific immunological activity of tumor-derived gp96 preparations.Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progressionDifferential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid ARegulatory T cells and tumour immunity - observations in mice and men.Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.Effect of interleukin 12 on tumor induction by 3-methylcholanthreneInhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine.
P2860
Q26801551-863BD693-5EDA-4058-8B71-251FA2510A23Q31023643-E23EACBD-D6B4-43B3-9F28-CE19A28F62F7Q33576035-2966133E-8089-47AA-B754-2377740789ABQ34026026-7FEC803C-1E0C-45BB-8F45-56E6365D0826Q34110762-05BECEC4-53C9-4B0B-90DA-97FA75AA828FQ34124707-8465C7C6-3E7F-4C5C-B1CD-08A4FF205D1AQ34146406-F015B977-28E1-4EA0-8E13-5DD883E544E4Q34432872-C0C74C69-B883-4651-AC75-C3E0F5FE4DC0Q34445730-E59C171A-F702-4271-9168-99942606ACF3Q34452657-A61A0AF3-47ED-4743-97E3-64D3505392A5Q34577679-29D52103-D550-4C99-8C1C-27B4C15D364DQ35106871-091DF273-E704-47CD-91C7-FAB09E363537Q35856375-1263009A-7F3F-4789-A216-7B141F0C1424Q35871253-27F64D3C-2D21-4EFC-8A30-2907D75DCE08Q35964158-7FEC7920-62D8-43E8-A767-F2AA2DE74DDAQ35987797-9C557400-2DC2-4E19-9202-07581E3B9690Q35992368-1E32D5D0-4827-4159-B789-7718AA1E6277Q36080957-4FA60DA6-5EBC-4B92-9694-9668EFE1802BQ36348717-CF3BB9EE-4042-4E2E-AE91-A604155D981CQ36349864-6D87182E-B229-45B1-AB64-5F22E011D5A7Q36350025-E82570E0-70DC-4DBE-8130-F82437ACBBA8Q36350238-F6D7ECF3-F97A-4B32-90BD-37B863DEC472Q36350552-0F5F4784-2FE6-4682-B227-8A2F7451B9C0Q36351161-20E420DE-2B25-40C2-A7EE-56F16DE6A951Q36351226-C1986B2D-514E-446A-8CFC-26B06E662D60Q36352895-A0BE941F-1CAF-475E-BC73-526DA20438E3Q36353344-A12783A2-14E9-44F5-A0E3-7D4600D40526Q36356458-34D41182-3BFE-4704-A661-EACBBB0AD1BDQ36357274-C9EDC59B-98B4-42D6-A9B4-05715736C85AQ36368193-43B96575-728E-4941-AE57-C7A5B10334E3Q36375248-B420A045-9237-4ECC-8E5B-9E49A883E727Q36376333-9088B5E0-3CF9-449F-BE5E-366A935995EAQ36399686-F350959B-3A2D-4501-A8B7-C184B0940F2CQ36399807-3824C49D-0A6A-4499-9F16-20328D7F1B21Q36967634-DCE21F86-431B-4906-8297-B851216F8BCEQ37027565-703AD587-7A7D-4172-8B61-61DD24246CE9Q37055402-9D9A6DA6-086E-4A5F-AFA1-F75A2DCE0038Q37088617-D50C050E-F27A-4EFD-879D-4116F1C95215Q37269591-A4F534CC-9C7E-4CB5-BEEA-71F5622B4D91Q37297514-BD4C6D90-9B50-4D17-BB74-55259C36CAE1
P2860
Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Generation and decay of the im ...... n of Ly-1-2+ effector T cells.
@en
type
label
Generation and decay of the im ...... n of Ly-1-2+ effector T cells.
@en
prefLabel
Generation and decay of the im ...... n of Ly-1-2+ effector T cells.
@en
P2860
P356
P1476
Generation and decay of the im ...... n of Ly-1-2+ effector T cells.
@en
P2093
P2860
P304
P356
10.1084/JEM.159.5.1295
P407
P577
1984-05-01T00:00:00Z